Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Zyprexa IM Launch Planned For 2001; 2Q Sales Top $550 Mil.

Executive Summary

Lilly hopes to introduce an intramuscular formulation of the antipsychotic Zyprexa by mid-2001.
Advertisement

Related Content

Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted
Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted
Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee
Zeldox QTc Prolongation Is Less Severe Than Serlect, Pfizer Tells Committee
Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee
Zeldox QTc Prolongation Is Less Severe Than Serlect, Pfizer Tells Committee
Lilly Sepsis Trial Prompts Biotech-Style Jump In Second Quarter
Lilly Zyprexa Zydis
Advertisement
UsernamePublicRestriction

Register

PS036379

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel